Search

Your search keyword '"Pawlik, T.M."' showing total 383 results
Start Over Author "Pawlik, T.M."
383 results on '"Pawlik, T.M."'

157. Proximal Cholangiocarcinoma: Tumor Depth Predicts Outcome

Author

Augustine, M., primary, Hong, S.M., additional, de Jong, M., additional, Goggins, M., additional, Schulick, R.D., additional, Wolfgang, C.L., additional, Edil, B.H., additional, Choti, M.A., additional, Anders, R., additional, and Pawlik, T.M., additional

Published
2010
Full Text
View/download PDF

163. QS322. Is it Safe to Observe Asymptomatic Branch Duct or Mixed-Type Intraductal Papillary Mucinous Neoplasms (IPMN) Less Than 3CM and Without a Solid Component?: The Pathological Findings of 16 Patients Who Underwent Pancreatectomy for This Condition

Author

Weiss, M.J., primary, Reddy, S., additional, Cameron, J.L., additional, Hruban, R.H., additional, Fishman, E.K., additional, Pawlik, T.M., additional, Schulick, R.D., additional, Edil, B.H., additional, and Wolfgang, C.L., additional

Published
2009
Full Text
View/download PDF

167. Adjuvant Chemoradiation Therapy after Surgical Resection for 1092 Cases of Pancreatic Adenocarcinoma: The Johns Hopkins Hospital - Mayo Clinic Collaborative Study of Pancreatic Cancer

Author

Hsu, C.C., primary, Herman, J.M., additional, Corsini, M.M., additional, Winter, J.M., additional, Callister, M.D., additional, Cameron, J.L., additional, Pawlik, T.M., additional, Swartz, M.J., additional, Gunderson, L.L., additional, and Miller, R.C., additional

Published
2008
Full Text
View/download PDF

185. Long-term follow-up of hepatic adenoma and adenomatosis: analysis of size change on imaging with histopathological correlation.

Author

Shao, N., Pandey, A., Ghasabeh, M.A., Khoshpouri, P., Pandey, P., Varzaneh, F.N., Zarghampour, M., Fouladi, D., Pawlik, T.M., Anders, R.A., and Kamel, I.R.

Subjects
*LIVER tumors, *LIVER, *FOLLOW-up studies (Medicine), *COMPUTED tomography, *HEPATOCYTE nuclear factors, *DIAGNOSIS, *MAGNETIC resonance imaging
Abstract

Aim: To analyse the change in size on follow-up of hepatic adenomas (HAs) and adenomatosis, and to investigate the relationship of imaging features with size change.Materials and Methods: The study included 44 patients (142 lesions) who underwent magnetic resonance imaging (MRI) or computed tomography (CT) for diagnosis and follow-up of HA. The imaging features and percentage change in maximum tumour dimension were observed over a follow-up duration of up to 139 months.Results: With an average follow-up of 43 months, 37% lesions decreased in size, 58% were stable, 4% increased; one lesion regressed completely. Adenomas were stratified into size groups (<3, 3-5, and ≥5 cm). Size change among the three groups was similar (p>0.05). Percent size change was different for lesions followed for ≤12 months (-7.2%) compared with lesions followed for 13-60 months (-20.5%), and those followed for ≥60 months (-23.5%; p<0.05); there was no difference between lesions followed for 13-60 months and ≥60 months (p=0.523). Baseline size and percent size change was similar between the hepatocyte nuclear factor 1α-inactivated HA (HA-H) and inflammatory HA (HA-I) subtype (p>0.05).Conclusion: Most adenomas were either stable or regressed on follow-up. Size change was independent of baseline size. After an initial size decrease within 5 years, no further size reduction was noted on extended follow-up. The percent size change in the HA-H and HA-I subtype was similar. [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

188. Clinical Features of Recurrence After Hepatic Resection for Early-stage Hepatocellular Carcinoma and Long-term Survival Outcomes of Patients with Recurrence - A Multi-institutional Analysis contained 1424 cases.

Author

Yao, L.-Q., Yang, T., Wang, M.-D., Li, C., Liang, L., Xing, H., Wu, H., Sun, L.-Y., Quan, B., Yan, W.-T., Shen, F., Wu, M.-C., Lau, W.Y., Pawlik, T.M., Xu, X.-F., Li, J.-D., Shao, C.-H., Diao, Y.-K., Peng, Z., and Jia, H.-D.

Subjects
*SURVIVAL rate, *HEPATOCELLULAR carcinoma, *DISEASE relapse, *CANCER relapse
Published
2022
Full Text
View/download PDF

191. Tumor necrosis impacts prognosis of patients undergoing resection for T1 intrahepatic cholangiocarcinoma: implications for modification of 8th AJCC T classification.

Author

Tsilimigras, D.I., Guglielmi, A., Aldrighetti, L., Bauer, T.W., Alexandrescu, S., Poultsides, G.A., Maithel, S.K., Marques, H.P., Martel, G., Pulitano, C., Shen, F., Soubrane, O., Koerkamp, B.G., Endo, I., and Pawlik, T.M.

Subjects
*PROGNOSIS, *CHOLANGIOCARCINOMA, *CLASSIFICATION, *PATIENTS
Published
2021
Full Text
View/download PDF

199. Parenchymal sparing versus anatomical hepatectomies in patients with multifocal (=4 tumors) colorectal liver metastasis: Results of an international multi-institutional analysis.

Author

Bagante, F., Ruzzenente, A., Ratti, F., Beal, E.W., Alexandrescu, S., Makris, E.A., Poultsides, G.A., Margonis, G.A., Weiss, M.J., Iacono, C., Popescu, I., Aldrighetti, L., Guglielmi, A., and Pawlik, T.M.

Subjects
*LIVER metastasis, *SURGICAL excision, *SURVIVAL analysis (Biometry), *TUMORS, *LIVER surgery, *PORTAL vein surgery
Published
2020
Full Text
View/download PDF

200. The concept of therapeutic hierarchy for patients with hepatocellular carcinoma: A multicenter cohort study

Author

Antonio Colecchia, Antonio Gasbarrini, Francesco Giuseppe Foschi, Alessandro Vitale, Luisa Benvegnù, Gerardo Nardone, Gabriele Missale, Timothy M. Pawlik, Fabio Farinati, Umberto Cillo, Rodolfo Sacco, Edoardo G. Giannini, Gianluca Svegliati-Baroni, Filomena Morisco, Mauro Bernardi, Anna Chiara Frigo, Lucia Napoli, Marco Zoli, Franco Trevisani, Franco Borzio, Martina Felder, Gian Ludovico Rapaccini, Eugenio Caturelli, Maria Di Marco, Fabio Marra, Giuseppe Cabibbo, Alberto Masotto, Francesco Ciccarese, Roberto Virdone, Vitale A., Farinati F., Pawlik T.M., Frigo A.C., Giannini E.G., Napoli L., Ciccarese F., Rapaccini G.L., Di Marco M., Caturelli E., Zoli M., Borzio F., Sacco R., Cabibbo G., Virdone R., Marra F., Felder M., Morisco F., Benvegnu L., Gasbarrini A., Svegliati-Baroni G., Foschi F.G., Missale G., Masotto A., Nardone G., Colecchia A., Bernardi M., Trevisani F., Cillo U., Vitale, A., Farinati, F., Pawlik, T. M., Frigo, A. C., Giannini, E. G., Napoli, L., Ciccarese, F., Rapaccini, G. L., Di Marco, M., Caturelli, E., Zoli, M., Borzio, F., Sacco, R., Cabibbo, G., Virdone, R., Marra, F., Felder, M., Morisco, F., Benvegnu, L., Gasbarrini, A., Svegliati-Baroni, G., Foschi, F. G., Missale, G., Masotto, A., Nardone, G., Colecchia, A., Bernardi, M., Trevisani, F., and Cillo, U.

Subjects
Male, Oncology, Sorafenib, medicine.medical_specialty, Prognostic variable, Carcinoma, Hepatocellular, medicine.medical_treatment, treatment selection, Liver transplantation, hepatocellular carcinoma, prognostic variable, survival benefit, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, medicine, Humans, Aged, Neoplasm Staging, Retrospective Studies, Aged, 80 and over, Hepatology, Performance status, business.industry, Liver Neoplasms, Hazard ratio, Middle Aged, medicine.disease, Confidence interval, Italy, 030220 oncology & carcinogenesis, Hepatocellular carcinoma, Female, 030211 gastroenterology & hepatology, Liver cancer, business, medicine.drug
Abstract

Background: The Italian Liver Cancer (ITA.LI.CA) prognostic system for patients with hepatocellular carcinoma (HCC) has recently been proposed and validated. We sought to explore the relationship among the ITA.LI.CA prognostic variables (ie tumour stage, functional score based on performance status and Child-Pugh score, and alpha-fetoprotein), treatment selection and survival outcome in HCC patients. Patients and Methods: We analysed 4,867 consecutive HCC patients undergoing six main treatment strategies (liver transplantation, LT; liver resection, LR; ablation, ABL; intra-arterial therapy, IAT; Sorafenib, SOR; and best supportive care, BSC) and enrolled during 2002-2015 in a multicenter Italian database. In order to control pretreatment imbalances in observed variables, a machine learning methodology was used and inverse probability of treatment weights (IPTW) was calculated. An IPTW-adjusted multivariate survival model that included ITA.LI.CA prognostic variables, treatment period and treatment strategy was then developed. The survival benefit of HCC treatments was described as a hazard ratio (95% confidence interval), using BSC as a reference value and as predicted median survival. Results: After the IPTW, the six treatment groups became well balanced for most baseline characteristics. In the IPTW-adjusted multivariate survival model, treatment strategy was found to be the strongest survival predictor, irrespective of ITA.LI.CA prognostic variables and treatment period. The survival benefit of different therapies over BSC was: LT=0.19 (0.18-0.20); RES=0.40 (0.37-0.42); ABL 0.42 (0.40-0.44); IAT=0.58 (0.55-0.61); SOR=0.92 (0.87-0.97). This multivariate model was then used to predict median survival for each therapy within each ITA.LI.CA stage. Conclusion: The concept of therapeutic hierarchy was established within each ITA.LI.CA stage.

Published
2019

Catalog

Books, media, physical & digital resources
See catalog results